Christopher Haqq's Net Worth
$10.6 Million
Who is Christopher Haqq?
Christopher Haqq has an estimated net worth of $10.6 Million. This is based on reported shares across multiple companies, which include Atara Biotherapeutics, Inc., Surrozen, Inc./DE, and Elicio Therapeutics, Inc..
SEC CIK
Christopher Haqq's CIK is 0001612095
Past Insider Trading and Trends
2015 was Christopher Haqq's most active year for acquiring shares with 6 total transactions. Christopher Haqq's most active month to acquire stocks was the month of January. 2015 was Christopher Haqq's most active year for disposing of shares, totalling 19 transactions. Christopher Haqq's most active month to dispose stocks was the month of January. 2018 saw Christopher Haqq paying a total of $275,000.00 for 78,053 shares, this is the most they've acquired in one year. In 2018 Christopher Haqq cashed out on 125,556 shares for a total of $4,162,774.98, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Atara Biotherapeutics, Inc. (ATRA) Snapshot price: $9.1465
EVP, R&D & Chief Scientific Of
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.28% | -775.00 |
$39.59 | -$30,682.25 | 271.94K |
Scheduled
|
Feb 15
| ||
Form 4
| -4.87% | -13.97K |
$38.55 | -$538,736.25 | 272.72K |
Scheduled
|
Feb 11
| ||
Form 4
| +0.39% | 1.11K |
$38.60 | -$536,088.16 | 286.69K |
Scheduled
|
Feb 6
| ||
Form 4
| -0.27% | -775.00 |
$33.81 | -$26,202.75 | 285.58K |
Scheduled
|
Nov 15
| ||
Form 4
| -4.50% | -13.50K |
$43.08 | -$581,580.00 | 286.36K |
Scheduled
|
Sep 26
| ||
Form 4
| -9.51% | -31.50K |
$40.17 | -$1,265,330.49 | 299.86K |
Scheduled
|
Sep 24 - Sep 25
| ||
Form 4
| -0.23% | -775.00 |
$37.54 | -$29,093.50 | 331.36K |
Scheduled
|
Aug 15
| ||
Form 4
| -0.23% | -775.00 |
$28.15 | -$892,480.42 | 332.13K |
Scheduled
|
May 15
| ||
Form 4
| -5.22% | -18.33K |
$39.79 | -$729,264.52 | 332.9K |
Scheduled
|
Mar 26
| ||
Form 4
| +0.16% | 553 |
—
|
—
| 351.23K |
Feb 15
| |||
Form 4
| -1.38% | -4.92K |
$41.70 | -$205,372.50 | 350.68K |
Feb 9
| |||
Form 4
| +3.82% | 13.07K |
$35.80 | -$158,450.80 | 355.6K |
Feb 6
| |||
Form 4
| -0.23% | -775.00 |
$13.36 | -$21,429.44 | 342.53K |
Scheduled
|
Nov 15
| ||
Form 4
| -1.72% | -6.00K |
$14.35 | -$86,100.00 | 343.31K |
Scheduled
|
Oct 16
| ||
Form 4
| -1.69% | -6.00K |
$15.30 | -$91,800.00 | 349.31K |
Scheduled
|
Sep 15
| ||
Form 4
| -1.87% | -6.78K |
$14.75 | -$112,159.00 | 355.31K |
Scheduled
|
Aug 15
| ||
Form 4
| -1.63% | -6.00K |
$14.92 | -$89,520.00 | 362.08K |
Scheduled
|
Jul 17
| ||
Form 4
| -1.60% | -6.00K |
$12.65 | -$75,900.00 | 368.08K |
Scheduled
|
Jun 15
| ||
Form 4
| -1.78% | -6.78K |
$14.99 | -$113,983.96 | 374.08K |
Scheduled
|
May 15
| ||
Form 4
| -1.55% | -6.00K |
$17.28 | -$103,680.00 | 380.86K |
Scheduled
|
Apr 17
| ||
Form 4
| -1.53% | -6.00K |
$19.60 | -$117,600.00 | 386.86K |
Scheduled
|
Mar 15
| ||
Form 4
| -1.70% | -6.78K |
$15.49 | -$117,785.96 | 392.86K |
Scheduled
|
Feb 15
| ||
Form 4
| -3.38% | -13.97K |
$15.46 | -$216,053.50 | 399.63K |
Scheduled
|
Feb 9
| ||
Form 4
| +13.59% | 49.5K |
—
|
—
| 413.61K |
Feb 6
| |||
Form 4
| -1.62% | -6.00K |
$14.27 | -$85,620.00 | 364.11K |
Scheduled
|
Jan 17
| ||
Form 4
| -1.60% | -6.00K |
$15.40 | -$92,400.00 | 370.11K |
Scheduled
|
Dec 15
| ||
Form 4
| -1.84% | -7.07K |
$17.85 | -$126,163.80 | 376.11K |
Scheduled
|
Nov 21
| ||
Form 4
| -0.20% | -775.00 |
$19.95 | -$31,999.80 | 383.17K |
Scheduled
|
Nov 15
| ||
Form 4
| +30.62% | 90K |
—
|
—
| 383.95K |
Sep 22
| |||
Form 4
| -0.18% | -517.00 |
$22.32 | -$30,040.68 | 293.95K |
Scheduled
|
Aug 15
| ||
Form 4
| -0.26% | -775.00 |
$15.57 | -$24,989.85 | 294.46K |
Scheduled
|
May 16
| ||
Form 4
| -0.80% | -2.38K |
$15.43 | -$49,499.44 | 295.24K |
Scheduled
|
Feb 16
| ||
Form 4
| +23.13% | 55.9K |
—
|
—
| 297.62K |
Feb 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 17
| |||
Form 4
| +0.34% | 829 |
—
|
—
| 241.72K |
Nov 16
| |||
Form 4
| -2.03% | -5.00K |
$41.99 | -$209,961.00 | 240.89K |
Scheduled
|
Aug 31
| ||
Form 4
| -0.31% | -775.00 |
$45.91 | -$73,632.00 | 245.89K |
Scheduled
|
Aug 17
| ||
Form 4
| -1.00% | -2.50K |
$55.43 | -$138,575.00 | 246.66K |
Scheduled
|
Jul 31
| ||
Form 4
| -0.99% | -2.50K |
$62.94 | -$157,353.00 | 249.16K |
Scheduled
|
Jul 15
| ||
Form 4
| -0.98% | -2.50K |
$51.68 | -$129,196.00 | 251.66K |
Scheduled
|
Jul 1
| ||
Form 4
| -2.87% | -7.50K |
$46.42 | -$348,116.00 | 254.16K |
Scheduled
|
Jun 15
| ||
Form 4
| -0.95% | -2.50K |
$41.47 | -$103,664.50 | 261.67K |
Scheduled
|
Jun 1
| ||
Form 4
| +0.97% | 2.54K |
$37.30 | -$70,385.10 | 264.17K |
May 15
| |||
Form 4
| +4.98% | 12.4K |
—
|
—
| 261.63K |
Jan 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Surrozen, Inc./DE (SRZN) Snapshot price: $9.35
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 30K |
—
|
—
| 30K |
Aug 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Elicio Therapeutics, Inc. (ELTX) Snapshot price: $3.96
See Remarks
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||